Takeda Archives -

Two weeks after reporting disappointing results for its lead coeliac disease therapy, 9 Meters Biopharma will draw some

After coeliac fail, 9 Meters plots phase 3 in short bowel syndrome

https://pharmaphorum.com/news/after-coeliac-fail-9-meters-plots-phase-3-in-short-bowel-syndrome/

News/ News/ R&D

Takeda bolsters data for dengue jab as regulatory reviews roll on

Phil Taylor dengue fever, Dengue vaccine, Dengvaxia, Sanofi, Takeda, vaccine 0 Comment

Takeda has reported positive new, long-term results in its pivotal trial of dengue fever vaccine TAK-003 that builds

Takeda bolsters data for dengue jab as regulatory reviews roll on

https://pharmaphorum.com/news/takeda-bolsters-data-for-dengue-jab-as-regulatory-reviews-roll-on/

Deep Dive/ Market Access/ Views & Analysis/ Views and analysis

Closing the digital expectation gap in pharma

mike.hammerton@pharmaphorum.com Deep Dive, Deep Dive: Market Access, Jan Deman, market access, Takeda 0 Comment

Jan Deman is Takeda’s head of digital customer experience for Europe and Canada. But he’d prefer not to

Closing the digital expectation gap in pharma

https://pharmaphorum.com/market-access-2/closing-the-digital-expectation-gap-in-pharma/

Digital/ News/ News

Takeda, Daiichi-backed wearable study planned in Japan

Phil Taylor Daiichi Sankyo, digital, digital health, Takeda, wearable 0 Comment

A study that will look at the feasibility of tracking people’s lifestyle habits for an extended period using

Takeda, Daiichi-backed wearable study planned in Japan

https://pharmaphorum.com/news/takeda-daiichi-backed-wearable-study-planned-in-japan/

Deep Dive/ Market Access/ Views & Analysis/ Views and analysis

Deep Dive: Market Access

mike.hammerton@pharmaphorum.com Axon, Deep Dive, market access, Medscape, Novartis, Takeda 0 Comment

For life science companies around the world, enabling faster access to innovative drugs and therapies is a complicated

Deep Dive: Market Access

https://pharmaphorum.com/market-access-2/deep-dive-market-access-2022/

Market Access/ News/ News

Takeda spinout Phathom claims its first FDA approvals

Phil Taylor gastroenterology, Helicobacter pylori, Phathom Pharmaceuticals, regulatory approval, Takeda, vonoprazan, Voquezna 0 Comment

Three years after it was formed as a spinout of Japanese drugmaker Takeda, Phathom Pharmaceuticals has racked up

Takeda spinout Phathom claims its first FDA approvals

https://pharmaphorum.com/news/takeda-spinout-phathom-claims-its-first-fda-approvals/

Market Access/ News/ News

NHS grants fast-track access to Takeda’s lung cancer drug Exkivity

Phil Taylor access, EGFR, Exkivity, NHS, Non-small cell lung cancer, Oncology, Project Orbis, Takeda 0 Comment

Takeda has secured UK approval for its lung cancer therapy Exkivity, with an NHS access deal that could

NHS grants fast-track access to Takeda’s lung cancer drug Exkivity

https://pharmaphorum.com/news/nhs-grants-fast-track-access-to-takedas-lung-cancer-drug-exkivity/

Molecular, DNA and atom model in science research lab

News/ News/ R&D

Takeda grows in gene therapies again with $2bn Code Bio deal

Phil Taylor Code Bio, gene therapy, partnering, Takeda 0 Comment

Takeda has forged another alliance as it continues a push into gene therapy, agreeing a deal worth up

Takeda grows in gene therapies again with $2bn Code Bio deal

https://pharmaphorum.com/news/takeda-grows-in-gene-therapies-again-with-2bn-code-bio-deal/

Market Access/ News/ News

FDA knocks back Takeda’s blockbuster hope TAK-721

Phil Taylor eosinophilic oesophagitis, Immunology and inflammation, pipeline, Takeda 0 Comment

Japanese drugmaker Takeda has suffered a blow to its late-stage pipeline, after the FDA rejected its marketing application

FDA knocks back Takeda’s blockbuster hope TAK-721

https://pharmaphorum.com/news/fda-knocks-back-takedas-blockbuster-hope-tak-721/

Trending

Takeda

Login